600196 复星医药
交易中 02-06 10:40:52
资讯
新帖
简况
复星医药子公司复宏汉霖携手卫材就抗PD-1单抗汉斯状 达成日本市场合作
复星医药官微 · 02-05 20:11
复星医药子公司复宏汉霖携手卫材就抗PD-1单抗汉斯状 达成日本市场合作
复星医药子公司环磷酰胺注射液药品注册申请获国家药监局受理
美股速递 · 02-05 17:27
复星医药子公司环磷酰胺注射液药品注册申请获国家药监局受理
复星医药(02196)：环磷酰胺注射液的药品注册申请获受理
智通财经 · 02-05 17:27
复星医药(02196)：环磷酰胺注射液的药品注册申请获受理
复星医药(600196.SH)控股子公司复宏汉霖与Eisai签订许可协议
智通财经 · 02-05 16:46
复星医药(600196.SH)控股子公司复宏汉霖与Eisai签订许可协议
复星医药：复迈宁新适应症上市申请获优先审评受理
财中社 · 02-05 16:43
复星医药：复迈宁新适应症上市申请获优先审评受理
两会对话｜复星医药文德镛：商保创新药目录落地仍需突破三个瓶颈
澎湃新闻 · 02-05 07:56
两会对话｜复星医药文德镛：商保创新药目录落地仍需突破三个瓶颈
复星医药（600196）披露拟分拆子公司复星安特金赴港上市，2月4日股价上涨1.14%
证券之星 · 02-04 22:39
复星医药（600196）披露拟分拆子公司复星安特金赴港上市，2月4日股价上涨1.14%
复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务
证券日报 · 02-04 21:37
复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务
复星医药完成10亿元科技创新债券发行，发行利率2.4%
财中社 · 02-03 17:14
复星医药完成10亿元科技创新债券发行，发行利率2.4%
每周股票复盘：复星医药（600196）新增一位CFO背景副总裁
证券之星 · 02-01
每周股票复盘：复星医药（600196）新增一位CFO背景副总裁
复星医药（600196）披露控股子公司药品获临床试验批准的公告，1月27日股价下跌1.7%
证券之星 · 01-27
复星医药（600196）披露控股子公司药品获临床试验批准的公告，1月27日股价下跌1.7%
复星医药最新公告：聘任孟凌媛为公司副总裁
证券之星 · 01-27
复星医药最新公告：聘任孟凌媛为公司副总裁
复星医药：复宏汉霖及子公司药品临床试验获批
财中社 · 01-27
复星医药：复宏汉霖及子公司药品临床试验获批
复星医药控股股东复星高科技质押率降至49.54%
中金财经 · 01-26
复星医药控股股东复星高科技质押率降至49.54%
每周股票复盘：复星医药（600196）拟分拆复星安特金赴港上市
证券之星 · 01-25
每周股票复盘：复星医药（600196）拟分拆复星安特金赴港上市
复星医药（600196）股东上海复星高科技(集团)有限公司质押3200万股，占总股本1.2%
证券之星 · 01-23
复星医药（600196）股东上海复星高科技(集团)有限公司质押3200万股，占总股本1.2%
复星医药：近年来公司持续在创新研发等多维度践行国际化战略
证券日报 · 01-22
复星医药：近年来公司持续在创新研发等多维度践行国际化战略
复星医药重酒石酸去甲肾上腺素注射液药品注册申请获批准
美股速递 · 01-22
复星医药重酒石酸去甲肾上腺素注射液药品注册申请获批准
复星医药最新公告：分拆所属子公司复星安特金至香港联交所主板上市获董事会批准
证券之星 · 01-22
复星医药最新公告：分拆所属子公司复星安特金至香港联交所主板上市获董事会批准
复星医药最新公告：控股子公司药品重酒石酸去甲肾上腺素注射液获注册批准
证券之星 · 01-22
复星医药最新公告：控股子公司药品重酒石酸去甲肾上腺素注射液获注册批准
加载更多
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":26.71,"timestamp":1770345652000,"preClose":26.6,"halted":0,"volume":6443271,"delay":0,"changeRate":0.0041,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"交易中","change":0.11,"latestTime":"02-06 10:40:52","open":26.68,"high":26.75,"low":26.47,"amount":172000000,"amplitude":0.0105,"askPrice":26.71,"askSize":6,"bidPrice":26.7,"bidSize":67,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770348600000},"marketStatusCode":2,"adr":0,"adjPreClose":26.6,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":29.26,"lowLimit":23.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.48,"roa":"--","peRate":21.727813,"roe":"5.3%","epsLYR":1.04,"committee":-0.476515,"marketValue":71327000000,"turnoverRate":0.003,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.46,"timestamp":1770345643931,"preClose":20.52,"halted":0,"volume":803500,"delay":0,"premium":"-31.97"},"floatMarketCap":56585000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2609722603","title":"复星医药子公司复宏汉霖携手卫材就抗PD-1单抗汉斯状 达成日本市场合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2609722603","media":"复星医药官微","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609722603?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:11","pubTimestamp":1770293460,"startTime":"0","endTime":"0","summary":"2026年2月5日，上海&东京——卫材株式会社（总部：日本东京，首席执行官：内藤晴夫，以下简称“卫材”）与复宏汉霖（总部：中国上海，首席执行官：朱俊博士）今日共同宣布，双方已就抗P ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260205/c674591094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0012","BK0060","BK0175","BK0183","BK0188","BK0239","BK0196","BK0096","BK0028","BK0187","600196"],"gpt_icon":0},{"id":"1157102696","title":"复星医药子公司环磷酰胺注射液药品注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1157102696","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157102696?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:27","pubTimestamp":1770283630,"startTime":"0","endTime":"0","summary":"复星医药宣布，其子公司提交的环磷酰胺注射液药品注册申请，已正式获得国家药品监督管理局的受理。这一进展标志着该药物在中国市场的注册进程迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0196","BK0028","BK0187","BK0183","600196","BK0060","BK0239","BK0012","BK0188","BK0175"],"gpt_icon":0},{"id":"2609206403","title":"复星医药(02196)：环磷酰胺注射液的药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609206403","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609206403?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:27","pubTimestamp":1770283627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，近日，公司控股子公司吉斯美(武汉)制药有限公司就环磷酰胺注射液的药品注册申请获国家药品监督管理局受理。据悉，该药品为集团自主研发的化学药品，拟用于治疗患有以下疾病的成人和儿童患者：恶性淋巴瘤、霍奇金病、淋巴细胞性淋巴瘤、混合细胞型淋巴瘤、组织细胞性淋巴瘤、伯基特淋巴瘤、多发性骨髓瘤、白血病、蕈样肉芽肿、神经母细胞瘤、卵巢腺癌、视网膜母细胞瘤、乳腺癌。截至 2025 年 12 月，集团现阶段针对该药品的累计研发投入约为人民币 740 万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK0239","BK0028","BK1191","02196","BK1515","BK0175","BK0096","BK0187","BK1593","BK0183","BK0012","BK0188","BK0196","BK0060"],"gpt_icon":0},{"id":"2609322049","title":"复星医药(600196.SH)控股子公司复宏汉霖与Eisai签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2609322049","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609322049?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:46","pubTimestamp":1770281167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2026年2月5日，公司控股子公司复宏汉霖与Eisai签订《许可协议》，由复宏汉霖授予Eisai于许可区域(即日本)及领域开发、生产及商业化斯鲁利单抗注射液的权利。基于许可产品于许可区域的年度净销售额达成情况，Eisai应依约向复宏汉霖支付至多23,333万美元的销售里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","600196","BK1161","02196","HK0000165453.HKD","BK0096","BK0183","BK1593","BK0187","BK0012","BK1191","BK0188","BK0028","BK0239","HK0000320264.USD","BK0175","02696","HK0000320223.HKD","HK0000306701.USD","BK0060","BK1515","HK0000306685.HKD"],"gpt_icon":0},{"id":"2609432214","title":"复星医药：复迈宁新适应症上市申请获优先审评受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432214","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609432214?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:43","pubTimestamp":1770280995,"startTime":"0","endTime":"0","summary":"2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁?（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。截至2025年12月，针对该药品的累计研发投入约为6.63亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642780133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK1515","BK0060","BK0175","BK0028","BK0196","BK1191","BK1593","02196","600196","BK0187","BK0096","BK0188","BK0239","BK0012"],"gpt_icon":0},{"id":"2609131245","title":"两会对话｜复星医药文德镛：商保创新药目录落地仍需突破三个瓶颈","url":"https://stock-news.laohu8.com/highlight/detail?id=2609131245","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609131245?lang=zh_cn&edition=full","pubTime":"2026-02-05 07:56","pubTimestamp":1770249406,"startTime":"0","endTime":"0","summary":"“尽管政策取得积极进展，但商保创新药目录的落地和实施仍存在困难。”2月3日，上海市人大代表、复星医药副董事长文德镛在接受澎湃新闻记者独家专访时表达了上述观点。公开数据显示，当前创新药销售费用构成中，基本医疗保险承担44%，商业保险仅承担7%，剩余近半数费用需通过患者自费或其他渠道解决，商保保障效能尚未充分释放。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642106781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642106781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","159992","BK0188","BK1574","BK1191","BK1161","BK0060","BK0175","BK1593","06978","BK0096","BK0028","BK0012","BK0196","600196","BK0239","BK0183","02196","BK1515"],"gpt_icon":0},{"id":"2608398235","title":"复星医药（600196）披露拟分拆子公司复星安特金赴港上市，2月4日股价上涨1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398235","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608398235?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:39","pubTimestamp":1770215954,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，复星医药报收于26.64元，较前一交易日上涨1.14%，最新总市值为711.4亿元。该股当日开盘26.35元，最高26.64元，最低26.12元，成交额达3.84亿元，换手率为0.69%。近日，上海复星医药（集团）股份有限公司披露拟分拆所属子公司复星安特金至香港联交所主板上市。公司董事会已审议通过相关议案，提请股东大会审议分拆方案及相关事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","600196","BK0060","BK1191","BK0096","02196","BK0187","BK0175","BK0196","BK1593","BK0183","BK0188","BK0012","BK0239","BK0028"],"gpt_icon":0},{"id":"2608362077","title":"复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362077","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362077?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:37","pubTimestamp":1770212245,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，复星医药在互动平台回答投资者提问时表示，公司自1994年创立于上海，是一家植根中国、创新驱动的全球化医药健康产业集团。目前，公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务；其中，制药是公司的核心主营业务，也是公司品牌建设的重要承载。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641720167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1100","BK0028","BK0060","BK0096","09997","BK0183","600196","BK0239","01477","BK4585","BK4581","09996","LABU","BK0196","02196","BK1191","BK1574","159883","BK0012","BK0187","XBI","BK0188","159760","XLV","BK1222","BK0175","BK1515","BK1583","BK4588"],"gpt_icon":0},{"id":"2608829539","title":"复星医药完成10亿元科技创新债券发行，发行利率2.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608829539","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608829539?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:14","pubTimestamp":1770110041,"startTime":"0","endTime":"0","summary":"2月3日，复星医药（600196/02196）发布公告，公司完成2026年度第一期科技创新债券发行，实际发行总额为10亿元，期限为2年，发行利率2.40%。2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640171119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0175","BK1593","BK0012","BK0187","BK0188","BK1191","BK0196","02196","BK1515","600196","BK4581","BK4588","BK4585","BK0183","BK0239","BK0060","BK0096"],"gpt_icon":0},{"id":"2608807738","title":"每周股票复盘：复星医药（600196）新增一位CFO背景副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807738","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608807738?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:22","pubTimestamp":1769883732,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，复星医药报收于26.67元，较上周的27.57元下跌3.26%。公司公告汇总：复星医药为多家控股子公司提供合计15.39亿元担保，实际对外担保余额达227.63亿元。公司公告汇总复星医药第十届董事会第二十三次会议于2026年1月26日召开，审议通过聘任孟凌媛女士为公司副总裁，任期自当日起至本届董事会任期届满。复星医药控股子公司复宏汉霖收到国家药监局批准，同意注射用HLX43联合HLX07及斯鲁利单抗注射液用于晚期实体瘤治疗的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","BK1593","BK0188","BK0196","BK1191","02196","BK1515","BK0012","BK0096","BK0187","BK0060","600196","BK0028","BK0175"],"gpt_icon":0},{"id":"2606873733","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，1月27日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606873733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606873733?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:52","pubTimestamp":1769525535,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，复星医药报收于27.68元，较前一交易日下跌1.7%，最新总市值为739.17亿元。近日，复星医药发布《关于控股子公司药品获临床试验批准的公告》。公告显示，公司控股子公司复宏汉霖收到国家药监局批准，同意注射用HLX43联合HLX07及斯鲁利单抗注射液用于晚期实体瘤治疗的临床试验。HLX43、HLX07及斯鲁利单抗均为自主研发或合作开发的创新型生物药，目前均处于临床试验阶段。全球范围内尚无同类联合用药方案获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700042306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","02196","BK1515","BK0239","600196","BK0187","BK0196","BK0188","BK1191","BK0183","BK0028","BK1593","BK0096","BK0012","BK0060"],"gpt_icon":0},{"id":"2606020402","title":"复星医药最新公告：聘任孟凌媛为公司副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2606020402","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606020402?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:32","pubTimestamp":1769506366,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司第十届董事会第二十三次会议同意聘任孟凌媛为公司副总裁，任期自2026年1月26日起至本届董事会任期届满之日止。孟凌媛曾任普华永道会计师事务所经理、高级经理，复星高科技审计高级总监等职务，拥有中国注册会计师资质。截至2026年1月26日，孟凌媛未持有公司股份，与公司不存在关联关系，也不存在不得担任上市公司高级管理人员的情形。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700029716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0239","BK1593","BK0188","BK0196","BK1191","02196","BK1515","BK0012","BK0096","BK0187","BK0060","600196","BK0028","BK0175"],"gpt_icon":0},{"id":"2606202415","title":"复星医药：复宏汉霖及子公司药品临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2606202415","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606202415?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:25","pubTimestamp":1769505958,"startTime":"0","endTime":"0","summary":"1月27日，复星医药（600196/02196）发布公告，公司的控股子公司复宏汉霖（02696）及其控股子公司获批同意注射用HLX43联合HLX07及斯鲁利单抗注射液用于晚期实体瘤治疗开展临床试验。截至2025年12月，公司及控股子公司现阶段针对该治疗方案的累计研发投入约为266万元。截至本公告日期，全球范围内尚无同类联合用药治疗方案获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273632288439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0060","BK0196","BK0175","HK0000306701.USD","BK0183","HK0000165453.HKD","BK1593","02196","600196","BK1515","HK0000320264.USD","02696","BK0188","HK0000306685.HKD","HK0000320223.HKD","BK0012","BK0187","BK1191","BK0028","BK1161","BK0096"],"gpt_icon":0},{"id":"2606215878","title":"复星医药控股股东复星高科技质押率降至49.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606215878","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606215878?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:14","pubTimestamp":1769418860,"startTime":"0","endTime":"0","summary":"中国经济网北京1月26日讯 复星医药 日前披露关于股东部分股份质押及解除质押的公告称，公司于2026年1月23日接到控股股东上海复星高科技(集团)有限公司的通知，其已将所持有的公司部分A股股份办理质押及解除质押手续。 复星高科技本次将3200万股股份质押给中国工商银行股份有限公司上海市长宁支行，质押期限自2026年1月22日至2028年1月26日，融资用途为偿还债务。该笔质押股份占复星高科技所持公司股份的3.33%，占公司总股本的1.20%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/26/20260126961437.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/26/20260126961437.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260126/31972679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0060","BK1593","BK1515","BK0096","BK0028","BK0196","BK0239","02196","BK0188","BK0175","BK1191","600196","BK0187","BK0012"],"gpt_icon":0},{"id":"2606234424","title":"每周股票复盘：复星医药（600196）拟分拆复星安特金赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234424","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234424?lang=zh_cn&edition=full","pubTime":"2026-01-25 01:54","pubTimestamp":1769277253,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，复星医药报收于27.57元，较上周的27.59元下跌0.07%。本周关注点来自公司公告汇总：复星医药拟分拆子公司复星安特金至香港联交所主板上市，已获董事会审议通过。本次分拆后，复星医药仍将保持对复星安特金的控制权，相关议案尚需提交股东会审议及监管机构批准。股本股东变化截至2026年1月22日，复星医药控股股东复星高科技持有公司961,424,455股，占总股本36.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0187","BK1593","BK0239","BK0183","BK1515","BK0175","BK0188","BK0196","BK1191","02196","BK0028","600196","BK0012","BK0060"],"gpt_icon":0},{"id":"2605479403","title":"复星医药（600196）股东上海复星高科技(集团)有限公司质押3200万股，占总股本1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605479403","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605479403?lang=zh_cn&edition=full","pubTime":"2026-01-23 18:37","pubTimestamp":1769164670,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药1月23日公开信息显示，股东上海复星高科技(集团)有限公司向中国工商银行股份有限公司上海市长宁支行合计质押3200.0万股，占总股本1.2%。质押详情见下表：截止本公告日，股东上海复星高科技(集团)有限公司已累计质押股份4.76亿股，占其持股总数的53.52%。复星医药主营业务：制药、医疗器械与医学诊断、医疗健康服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300032243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK1191","BK0183","BK1593","02196","BK0060","BK0187","BK0188","BK0239","BK0012","BK0175","BK0096","BK1515","BK0028","BK0196"],"gpt_icon":0},{"id":"2605491866","title":"复星医药：近年来公司持续在创新研发等多维度践行国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491866","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605491866?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:03","pubTimestamp":1769087023,"startTime":"0","endTime":"0","summary":"证券日报网讯1月22日，复星医药在互动平台回答投资者提问时表示，近年来，公司持续在创新研发、许可引进、生产运营及商业化等多维度践行国际化战略，提升运营效率，强化全球市场布局，并已主要覆盖美国、欧洲、非洲、印度和东南亚等海外市场。公司在欧盟市场的销售模式采用了多元化方式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627658039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","BK0028","02196","BK0183","BK1515","BK1593","BK0012","BK0196","BK1191","BK0239","BK0188","BK0175","BK0187","BK0096","600196"],"gpt_icon":0},{"id":"1108542084","title":"复星医药重酒石酸去甲肾上腺素注射液药品注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1108542084","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108542084?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:26","pubTimestamp":1769084773,"startTime":"0","endTime":"0","summary":"复星医药（600196）宣布，其重酒石酸去甲肾上腺素注射液的药品注册申请已获得监管部门批准。\n该药品获批将进一步丰富公司的心血管领域产品线，对提升市场竞争力具有积极意义。重酒石酸去甲肾上腺素作为临床常用急救药物，其上市将为患者提供更多治疗选择。\n此次获批体现了公司在创新药研发和注册申报方面的综合实力，也为未来业绩增长注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0239","BK0012","BK0196","BK0175","BK0096","BK0183","600196","BK0187","BK0188","BK0028"],"gpt_icon":0},{"id":"2605462947","title":"复星医药最新公告：分拆所属子公司复星安特金至香港联交所主板上市获董事会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462947","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462947?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:10","pubTimestamp":1769076641,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司第十届董事会第二十二次会议审议通过关于分拆所属子公司复星安特金（成都）生物制药股份有限公司至香港联交所主板上市的议案。该议案包括分拆上市符合相关法律法规规定、首次公开发行H股股票方案、分拆上市预案以及分拆上市符合《上市公司分拆规则（试行）》等内容。公司表示，本次分拆上市符合相关法律法规及监管机构的要求，具备可行性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200030530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0096","BK0175","BK0183","BK1191","600196","BK1593","BK0012","BK0187","BK0239","BK0188","BK0028","BK0060","BK0196","02196"],"gpt_icon":0},{"id":"2605462911","title":"复星医药最新公告：控股子公司药品重酒石酸去甲肾上腺素注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462911","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462911?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:09","pubTimestamp":1769076585,"startTime":"0","endTime":"0","summary":"复星医药公告称，公司控股子公司锦州奥鸿药业有限责任公司就重酒石酸去甲肾上腺素注射液的药品注册申请获国家药品监督管理局批准。该药品获批适应症包括急性低血压状态的血压恢复、心跳骤停的辅助治疗和心跳骤停复苏后的血压维持等。该药品为复星医药自主研发的化学药品，截至2025年12月，累计研发投入约为人民币874万元。该药品获批上市将进一步丰富复星医药的产品线，但具体销售情况可能受到多种因素影响，具有较大不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200030532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0175","BK1593","BK0012","BK0187","BK0188","BK1191","BK0196","02196","BK1515","600196","BK0183","BK0239","BK0060","BK0096"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770345655012,"stockEarnings":[{"period":"1week","weight":-0.0192},{"period":"1month","weight":-0.0274},{"period":"3month","weight":-0.0577},{"period":"6month","weight":0.0087},{"period":"1year","weight":0.1221},{"period":"ytd","weight":0.0042}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.2621},{"period":"ytd","weight":0.027}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}